Pages that link to "Q40722216"

The following pages link to Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in TSU-PR1 human cancer cells (Q40722216):

Displaying 27 items.

• BAD is a pro-survival factor prior to activation of its pro-apoptotic function (Q24298421) (← links)
• Steroid Hormone Receptor Signals as Prognosticators for Urothelial Tumor (Q26771960) (← links)
• Prostate cancer stem cells: the role of androgen and estrogen receptors (Q26778415) (← links)
• Involvement of the Androgen and Glucocorticoid Receptors in Bladder Cancer (Q26782760) (← links)
• Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis (Q31065757) (← links)
• ZEN and the art of breast health maintenance (Q34238685) (← links)
• Estrogens and Parkinson disease: novel approach for neuroprotection. (Q35141455) (← links)
• Estrogens and prostate cancer: etiology, mediators, prevention, and management. (Q35196710) (← links)
• Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action (Q35840621) (← links)
• Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status (Q36130890) (← links)
• Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: A meta-analysis of immunohistochemical studies (Q36330150) (← links)
• Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation (Q36522049) (← links)
• Chemoprevention of BBN-Induced Bladder Carcinogenesis by the Selective Estrogen Receptor Modulator Tamoxifen (Q36865011) (← links)
• Estrogen receptor-β expression and pharmacological targeting in bladder cancer. (Q37059473) (← links)
• Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia (Q37084590) (← links)
• High circulating estrogens and selective expression of ERβ in prostate tumors of Americans: implications for racial disparity of prostate cancer (Q37151639) (← links)
• Effects of zearalenone and alpha-Zearalenol in comparison with Raloxifene on T47D cells. (Q37329907) (← links)
• Role of oestrogen receptors in bladder cancer development (Q38099200) (← links)
• Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β. (Q39644350) (← links)
• Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma (Q40119298) (← links)
• Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. (Q40279953) (← links)
• The effect of raloxifene on Bax protein expression in breast carcinomas of postmenopausal women (Q44278738) (← links)
• Involvement of Akt in mitochondria-dependent apoptosis induced by a cdc25 phosphatase inhibitor naphthoquinone analog (Q44673360) (← links)
• Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder (Q46766883) (← links)
• Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. (Q46990082) (← links)
• Estrogens and Their Receptors in Prostate Cancer: Therapeutic Implications (Q49208785) (← links)
• Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications. (Q52589023) (← links)